MedTrace Logo

Prevention of Ischemic Events in Patients With Peripheral Arterial Disease

NCT00761969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1455

Last updated 2015-11-17

Study results available
· View outcomes & findings →

Summary

The PID-PAB study aims to test the efficacy of the European Guidelines on Cardiovascular Disease Prevention in patients with peripheral arterial disease. Survival, the rate of major atherothrombotic events (myocardial infarction, stroke, critical limb ischemia) and the incidence of revascularization procedures will be compared between a group of patients with stable peripheral arterial disease (PAD) and age- and sex-matched control subjects without PAD. Both groups will be receiving up-to-date medical care according to their cardiovascular risk based on the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Yearly follow-up is planned for 5 years. The PID PAB study aims to test (a) whether stable PAD is still an adverse prognostic indicator in spite of contemporary preventive measures, and (b) to what extent do contemporary preventive measures improve the prognosis of patients with PAD in comparison to historic controls, representing the natural history of the disease.

Conditions

  • Peripheral Arterial Disease

Interventions

OTHER

Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice

Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    collaborator OTHER

  • University of Ljubljana School of Medicine, Slovenia

    collaborator OTHER

  • Krka, d.d., Novo mesto, Slovenia

    collaborator UNKNOWN

  • KRKA

    lead INDUSTRY

Principal Investigators

  • Ales Blinc, MD, DSc · Dept of Vascular Diseases, University of Ljubljana Med Ctr

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Slovenia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761969 on ClinicalTrials.gov